Aadi Bioscience Q3 2023 Earnings Report $2.35 -0.04 (-1.67%) (As of 01:12 PM ET) Earnings HistoryForecast Aadi Bioscience EPS ResultsActual EPS-$0.60Consensus EPS -$0.73Beat/MissBeat by +$0.13One Year Ago EPSN/AAadi Bioscience Revenue ResultsActual Revenue$5.96 millionExpected Revenue$6.68 millionBeat/MissMissed by -$720.00 thousandYoY Revenue GrowthN/AAadi Bioscience Announcement DetailsQuarterQ3 2023Date11/8/2023TimeN/AConference Call ResourcesSlide DeckPress ReleaseAADI Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by DeFi Coin on Verge of Breakout! (Ad)The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! Aadi Bioscience Earnings HeadlinesShort Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Decreases By 12.7%December 15 at 1:19 AM | americanbankingnews.comUS Penny Stocks Under $90M Market Cap To WatchNovember 12, 2024 | finance.yahoo.comThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.December 18, 2024 | The Tomorrow Investor (Ad)Aadi Bioscience Faces Potential Financial Strain from Securities Class Action RisksNovember 9, 2024 | markets.businessinsider.comAadi Bioscience Reports Q3 2024 Earnings and GrowthNovember 7, 2024 | markets.businessinsider.comAadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate UpdateNovember 6, 2024 | prnewswire.comSee More Aadi Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aadi Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aadi Bioscience and other key companies, straight to your email. Email Address About Aadi BioscienceAadi Bioscience (NASDAQ:AADI), a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.View Aadi Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
